Asbesto como carcinógeno ocupacional en Colombia: desde la biología molecular hasta la salud pública

Nynäs P, Pukkala E, Vainio H, Oksa P. Cancer incidence in asbestos-exposed workers: an update on four finnish cohorts. Saf Health Work. 2017;8(2):169-74. https://doi.org/10.1016%2Fj.shaw.2016.11.003

Pira E, Donato F, Maida L, Discalzi G. Exposure to asbestos: past, present and future. J Thorac Dis. 2018;10(supl. 2):S237-45. https://doi.org/10.21037/jtd.2017.10.126

Abú-Shams K, Pascal I. Características, propiedades, patogenia y fuentes de exposición del asbesto. Anales Sis San Navarra. 2005;28(supl. 1):7-11. http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1137-66272005000200002&lng=es

Accinelli R, López L. Asbesto: la epidemia silenciosa. Acta Méd Peru. 2016;33(2):138-41. https://doi.org/10.35663/amp.2016.332.64

Bartrip P. History of asbestos related disease. Postgrad Med J. 2004;80(940):72-6. https://doi.org/10.1136/pmj.2003.012526

Cooke W. Fibrosis of the lungs due to the inhalation of asbestos dust. Br Med J. 1924;2(3317):140-2. https://doi.org/10.1136/bmj.2.3317.147

Cooke WE. Pulmonary Asbestosis. Br Med J. 1927;2(3491):1024-5. https://doi.org/10.1136/bmj.2.3491.1024

McDonald S. Histology of pulmonary asbestosis. Br Med J. 1927;2(3491):1025-6. https://doi.org/10.1136/bmj.2.3491.1025

Stayner L, Welch L, Lemen R. The worldwide pandemic of asbestos-related diseases. Annu Rev Public Health. 2013;34:205-16. https://doi.org/10.1146/annurev-publhealth-031811-124704

Wagner J, Sleggs C, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med. 1960;17(4):260-71. https://doi.org/10.1136/oem.17.4.260

Concha-Barrientos M, Nelson D, Driscoll T, Steenland N, Punnett L, Fingerhut M, et al. Chapter 21. Selected occupational risk factors 2004. En: Ezzati M, Lopez A, Rodgers A, Murray C, editores. Comparative Quantification of Health Risks [internet]. Ginebra, Suiza: World Health Organization. Disponible en: https://www.who.int/publications/i/item/chapter-21-selected-occupational-risk-factors

World Health Organization. Environmental health criteria 203: chrysotile asbestos [internet]. Ginebra, Suiza: World Health Organization; 1998. Disponible en: http://www.inchem.org/documents/ehc/ehc/ehc203.htm

World Health Organization. Asbestos and other natural mineral fibers [internet]. Ginebra, Suiza: WHO; 1986. Environmental Health Criteria 53. Disponible en: https://iris.who.int/handle/10665/37190

Congreso de la República de Colombia. Ley 1968, por el cual se prohíbe el uso de asbesto en el territorio nacional y se establecen garantías de protección a la salud de los colombianos [internet]; 2019. Disponible en: https://dapre.presidencia.gov.co/normativa/normativa/LEY%201968%20DEL%2011%20DE%20JULIO%20DE%202019.pdf

Rehrauer H, Wu L, Blum W, Pecze L, Henzi T, Serre-Beinier V, et al. How asbestos drives the tissue towards tumors: YAP activation, macrophage and mesothelial precursor recruitment, RNA editing, and somatic mutations. Oncogene. 2018;37(20):2645-59. https://doi.org/10.1038/s41388-018-0153-z

Hylebos M, Op de Beeck K, van den Ende J, Pauwels P, Lammens M, van Meerbeeck JP, et al. Molecular analysis of an asbestos-exposed Belgian family with a high prevalence of mesothelioma. Fam Cancer. 2018;17(4):569-76. https://doi.org/10.1007/s10689-018-0095-1

Cui Y, Wang Y, Deng J, Hu G, Dong F, Zhang Q. Chrysotile effects on the expression of anti-oncogene P53 and P16 and oncogene C-jun and C-fos in Wistar rats’ lung tissues. Environ Sci Pollut Res Int. 2018;25(23):22378-88. https://doi.org/10.1007/s11356-017-0063-6

Heintz N, Janssen-Heininger Y, Mossman B. Asbestos, lung cancers, and mesotheliomas: from molecular approaches to targeting tumor survival pathways. Am J Respir Cell Mol Biol. 2010;42(2):133-9. https://doi.org/10.1165/rcmb.2009-0206TR

Luis G, Hernández C, Rubio C, Frías I, Gutiérrez A, Hardisson A. Toxicología del asbesto. Cuad Med Forense. 2009;57:207-13. Disponible en: http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1135-76062009000300003&lng=es

Case B, Abraham J, Meeker G, Pooley F, Pinkerton K. Applying definitions of “asbestos” to environmental and “low-dose” exposure levels and health effects, particularly malignant mesothelioma. J Toxicol Environ Health B Crit Rev. 2011;14(1-4):3-39. https://doi.org/10.1080/10937404.2011.556045

Mossman B, Lippmann M, Hesterberg T, Kelsey K, Barchowsky A, Bonner J. Pulmonary endpoints (lung carcinomas and asbestosis) following inhalation exposure to asbestos. J Toxicol Environ Health B Crit Rev. 2011;14(1-4):76-121. https://doi.org/10.1080/10937404.2011.556047

Schneider F, Sporn T, Roggli V. Asbestos fiber content of lungs with diffuse interstitial fibrosis: an analytical scanning electron microscopic analysis of 249 cases. Arch Pathol Lab Med. 2010;134(3):457-61. https://doi.org/10.5858/134.3.457

Ospina D, Villegas V, Rodríguez-Leguizamón G, Rondón-Lagos M. Analyzing biological and molecular characteristics and genomic damage induced by exposure to asbestos. Cancer Manag Res. 2019;11:4997-5012. https://doi.org/10.2147/CMAR.S205723

Kumagai-Takei N, Yamamoto S, Lee S, Maeda M, Masuzzaki H, Sada N, et al. Inflammatory alteration of human t cells exposed continuously to asbestos. Int J Mol Sci. 2018;19(2):504. https://doi.org/10.3390/ijms19020504

Costa I, Guimarães F, Carvalho L, Castro V, Pereira N, Murata M, et al. Evaluation of genotoxic effects of asbestos on occupationally exposed workers in Brazil. Biomonitoring. 2016;3(1):25-33. http://dx.doi.org/10.1515/bimo-2016-0004

Srivastava R, Lohani M, Pant A, Rahman Q. Cyto-genotoxicity of amphibole asbestos fibers in cultured human lung epithelial cell line: Role of surface iron. Toxicol Ind Health. 2010;26(9):575-82. https://doi.org/10.1177/0748233710374464

Öner D, Ghosh M, Moisse M, Duca R, Coorens R, Vanoirbeek J, et al. Global and gene-specific DNA methylation effects of different asbestos fibres on human bronchial epithelial cells. Environ Int. 2018;115:301-11. https://doi.org/10.1016/j.envint.2018.03.031

Kettunen E, Hernandez-Vargas H, Cros M-P, Durand G, Le Calvez-Kelm F, Stuopelyte K, et al. Asbestos-associated genome-wide DNA methylation changes in lung cancer. Int J Cancer. 2017;141(10):2014-29. https://doi.org/10.1002/ijc.30897

Sage A, Martinez V, Minatel B, Pewarchuk M, Marshall E, MacAulay G, et al. Genomics and epigenetics of malignant mesothelioma. High Throughput. 2018;7(3):20. https://doi.org/10.3390/ht7030020

Galani V, Varouktsi A, Papadatos S, Mitselou A, Sainis I, Constantopoulos S, et al. The role of apoptosis defects in malignant mesothelioma pathogenesis with an impact on prognosis and treatment. Cancer Chemother Pharmacol. 2019;84(2):241-53. https://doi.org/10.1007/s00280-019-03878-3

Hiriart E, Deepe R, Wessels A. Mesothelium and malignant mesothelioma. J Dev Biol. 2019;7(2):7. https://doi.org/10.3390/jdb7020007

Benedetti S, Nuvoli B, Catalani S, Galati R. Reactive oxygen species a double-edged sword for mesothelioma. Oncotarget. 2015;6(19):16848-65. https://doi.org/10.18632/oncotarget.4253

Pietrofesa R, Velalopoulou A, Albelda S, Christofidou-Solomidou M. Asbestos induces oxidative stress and activation of nrf2 signaling in murine macrophages: chemopreventive role of the synthetic lignan secoisolariciresinol diglucoside (LGM2605). Int J Mol Sci. 2016;17(3):322. https://doi.org/10.3390/ijms17030322

Singh A, Kukreti R, Saso L, Kukreti S. Oxidative stress: role and response of short guanine tracts at genomic locations. Int J Mol Sci. 2019;20(17):4258. https://doi.org/10.3390/ijms20174258

Mesaros C, Worth A, Snyder N, Christofidou-Solomidou M, Vachani A, Albelda S, et al. Bioanalytical techniques for detecting biomarkers of response to human asbestos exposure. Bioanalysis. 2015;7(9):1157-73. https://doi.org/10.4155/bio.15.53

Wang Y, Jiang Z, Yan J, Ying S. HMGB1 as a potential biomarker and therapeutic target for malignant mesothelioma. Dis Markers. 2019;2019:4183157. https://doi.org/10.1155/2019/4183157

Carbone M, Yang H. Mesothelioma: recent highlights. Ann Transl Med. 2017;5(11):238. https://doi.org/10.21037/atm.2017.04.29

Zhou S, Liu L, Li H, Eilers G, Kuang Y, Shi S, et al. Multipoint targeting of the PI3K/mTOR pathway in mesothelioma. Br J Cancer. 2014;110(10):2479-88. https://doi.org/10.1038/bjc.2014.220

Bonelli M, Digiacomo G, Fumarola C, Alfieri R, Quaini F, Falco A, et al. Combined inhibition of CDK4/6 and PI3K/AKT/mTOR pathways induces a synergistic anti-tumor effect in malignant pleural mesothelioma cells. Neoplasia. 2017;19(8):637-48. https://doi.org/10.1016/j.neo.2017.05.003

Hylebos M, Van Camp G, van Meerbeeck JP, Op de Beeck K. The genetic landscape of malignant pleural mesothelioma: results from massively parallel sequencing. J Thorac Oncol. 2016;11(10):1615-26. https://doi.org/10.1016/j.jtho.2016.05.020

Melaiu O, Gemignani F, Landi S. The genetic susceptibility in the development of malignant pleural mesothelioma. J Thorac Dis. 2018;10(supl. 2):S246-52. https://doi.org/10.21037/jtd.2017.10.41

Nymark P, Wikman H, Hienonen-Kempas T, Anttila S. Molecular and genetic changes in asbestos-related lung cancer. Cancer Lett. 2008;265(1):1-15. https://doi.org/10.1016/j.canlet.2008.02.043

Ruosaari S, Hienonen-Kempas T, Puustinen A, Sarhadi VK, Hollmén J, Knuutila S, et al. Pathways affected by asbestos exposure in normal and tumour tissue of lung cancer patients. BMC Med Genomics. 2008;1:55. https://doi.org/10.1186/1755-8794-1-55

Rodríguez F. Diagnóstico y tratamiento del mesotelioma pleural maligno. Arch Bronconeumol. 2015;51(4):177-84. https://doi.org/10.1016/j.arbres.2014.06.005

Ascoli V, Minelli G, Cozzi I, Romeo E, Carnovale C, Ancona L, et al. Pathology reporting of malignant pleural mesothelioma first diagnosis: a population-based approach. Patholo Res Pract. 2016;212(10):886-92. https://doi.org/10.1016/j.prp.2016.07.010

Rossi G. Insert: The dark side of mesothelioma. En: Giordano A, Franco R, editores. Malignant pleural mesothelioma: A guide for clinicians. Estados Unidos: Academic Press; 2019. p. 91-7.

Cornelissen R, Aerts J. Biomarkers in malignant mesothelioma-an unfulfilled need or a waste of resources? J Thorac Dis. 2018;10(supl. 9):S1084-7. https://doi.org/10.21037/jtd.2018.03.128

Gillezeau C, van Gerwen M, Ramos J, Liu B, Flores R, Taioli E. Biomarkers for malignant pleural mesothelioma: a meta-analysis. Carcinogenesis. 2019;40(11):1320-31. https://doi.org/10.1093/carcin/bgz103

Wu L, Dell’Anno I, Lapidot M, Sekido Y, Chan M-L, Kohno M, et al. Progress of malignant mesothelioma research in basic science: A review of the 14th international conference of the international mesothelioma interest group (iMig2018). Lung Cancer. 2019;127:138-45. https://doi.org/10.1016/j.lungcan.2018.11.034

Faig J, Howard S, Levine E, Casselman G, Hesdorffer M, Ohar J. Changing pattern in malignant mesothelioma survival. Transl Oncol. 2015;8(1):35-9. https://doi.org/10.1016/j.tranon.2014.12.002

Cinausero M, Rihawi K, Sperandi F, Melotti B, Ardizzoni A. Chemotherapy treatment in malignant pleural mesothelioma: a difficult history. J Thorac Dis. 2018;10(supl. 2):S304-10. https://doi.org/10.21037/jtd.2017.10.19

MacLeod N, Chalmers A, O’Rourke N, Moore K, Sheridan J, McMahon L, et al. Is radiotherapy useful for treating pain in mesothelioma?: a phase II trial. J Thorac Oncol. 2015;10(6):944-50. https://doi.org/10.1097/JTO.0000000000000499

Van Schil P, Opitz I, Weder W, De Laet C, Domen A, Lauwers P, et al. Multimodal management of malignant pleural mesothelioma: where are we today? Eur Respir J. 2014;44(3):754-64. https://doi.org/10.1183/09031936.00207213

Robinson C, Dick I, Wise M, Holloway A, Diyagama D, Robinson B, et al. Consistent gene expression profiles in MexTAg transgenic mouse and wild type mouse asbestos-induced mesothelioma. BMC Cancer. 2015;15(1):983. https://doi.org/10.1186/s12885-015-1953-y

Lapidot M, Barash U, Vlodavsky I, Pass H. Heparanase inhibitors restrain mesothelioma. Oncotarget. 2018;9(96):36830-2. https://doi.org/10.18632/oncotarget.26243

Dell’anno I, Barone E, Lepori I, Migliore L, Agostini S, Melaiu O, et al. PO-220 RAN, a novel and promising gene for malignant pleural mesothelioma. ESMO Open. 2018;3(supl. 2):A106. https://doi.org/10.1136/esmoopen-2018-EACR25.255

Forde P, Scherpereel A, Tsao A. Use of immune checkpoint inhibitors in mesothelioma. Curr Treat Options Oncol. 2019;20(2):18. https://doi.org/10.1007/s11864-019-0613-x

Bickel A, Koneth I, Enzler-Tschudy A, Neuweiler J, Flatz L, Früh M. Pembrolizumab-associated minimal change disease in a patient with malignant pleural mesothelioma. BMC Cancer. 2016;16:656. https://doi.org/10.1186/s12885-016-2718-y

du Rusquec P, de Calbiac O, Robert M, Campone M, Frenel J. Clinical utility of pembrolizumab in the management of advanced solid tumors: an evidence-based review on the emerging new data. Cancer Manag Res. 2019;11:4297-312. https://doi.org/10.2147/CMAR.S151023

Popat S, Curioni-Fontecedro A, Polydoropoulou V, Shah R. LBA91_PRA multicentre randomized phase III trial comparing pembrolizumab (P) vs single agent chemotherapy (CT) for advanced pre-treated malignant pleural mesothelioma (MPM): results from the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial. Ann Oncol. 2019;30(supl. 5):v931. http://dx.doi.org/10.1093/annonc/mdz394.091

Baas P, Scherpereel A, Nowak A, Fujimoto N, Peters S, Tsao A, et al. ID:2908 First-Line Nivolumab + Ipilimumab vs Chemotherapy in Unresectable Malignant Pleural Mesothelioma: CheckMate 743. J Thor Oncol. 2020;15(10):e42. https://doi.org/10.1016/j.jtho.2020.08.004

Forde P, Sun Z, Anagnostou V, Kindler H, Purcell W, Goulart B, et al. PrE0505: Phase II multicenter study of anti-PD-L1, durvalumab, in combination with cisplatin and pemetrexed for the first-line treatment of unresectable malignant pleural mesothelioma (MPM)—A PrECOG LLC study. J Clin Oncol. 2020;38(supl. 15):9003. https://doi.org/10.1200/JCO.2020.38.15_suppl.9003

Cely-García M, Torres-Duque C, Durán M, Parada P, Sarmiento O, Breysse P, et al. Personal exposure to asbestos and respiratory health of heavy vehicle brake mechanics. J Expo Sci Environ Epidemiol. 2015;25(1):26-36. https://doi.org/10.1038/jes.2014.8

Instituto Nacional de Cancerología. Boletín legislativo y político: junio de 2019 [internet]. Bogotá, Colombia: INC. Disponible en: https://www.cancer.gov.co/files/libros/archivos/Bolet%C3%ADn%20Asbesto%202019.pdf

Ramos-Bonilla J, Cely-García M, Giraldo M, Comba P, Terracini B, Pasetto R, et al. An asbestos contaminated town in the vicinity of an asbestos-cement facility: the case study of Sibaté, Colombia. Environ Res. 2019;176:108464. https://doi.org/10.1016/j.envres.2019.04.031

Kazan-Allen L. Current Asbestos Bans [internet]; 2024. Disponible en: http://ibasecretariat.org/alpha_ban_list.php

Pasetto R, Terracini B, Marsili D, Comba P. Occupational burden of asbestos-related cancer in Argentina, Brazil, Colombia, and Mexico. Ann Glob Health. 2014;80(4):263-8. https://doi.org/10.1016/j.aogh.2014.09.003

Cely-García M, Sánchez M, Breysse P, Ramos-Bonilla J. Personal exposures to asbestos fibers during brake maintenance of passenger vehicles. Ann Occup Hyg. 2012;56(9):985-99. https://doi.org/10.1093/annhyg/mes030

Salazar N, Cely-García M, Breysse P, Ramos-Bonilla J. Asbestos exposure among transmission mechanics in automotive repair shops. Ann Occup Hyg. 2015;59(3):292-306. https://doi.org/10.1093/annhyg/meu093

Cely-García M, Curriero F, Giraldo M, Méndez L, Breysse P, Durán M, et al. Factors associated with non-compliance of asbestos occupational standards in brake repair workers. Ann Occup Hyg. 2016;60(8):1020-35. https://doi.org/10.1093/annhyg/mew028

Cely-García M, Curriero F, Sánchez-Silva M, Breysse P, Giraldo M, Méndez L, et al. Estimation of personal exposure to asbestos of brake repair workers. J Expo Sci Environ Epidemiol. 2017;27(4):417-26. https://doi.org/10.1038/jes.2016.76

Vimercati L, Cavone D, Lovreglio P, De Maria L, Caputi A, Ferri G, et al. Environmental asbestos exposure and mesothelioma cases in Bari, Apulia region, southern Italy: a national interest site for land reclamation. Environ Sci Pollut Res Int. 2018;25(16):15692-701. https://doi.org/10.1007/s11356-018-1618-x

Musti M, Pollice A, Cavone D, Dragonieri S, Bilancia M. The relationship between malignant mesothelioma and an asbestos cement plant environmental risk: a spatial case–control study in the city of Bari (Italy). Int Arch Occup Environ Health. 2009;82(4):489-97. https://doi.org/10.1007/s00420-008-0358-5